Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion

Leukemia volume 22, pages 1273–1274 (2008)Cite this article

The treatment options available in cases of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are very limited. In a recent issue of Leukemia, Taksin et al.1 described the high efficacy and safety of fractionated doses of gemtuzumab ozogamicin (GO) as induction therapy in patients with relapsed AML; fractionated doses of GO (3 mg m−2) were used on days 1, 4 and 7 for one course of therapy, with 26% of patients achieving complete remission (CR) and 7% achieving CR with incomplete platelet recovery (CRp) with low toxicity.

Here, we report an adult patient with AML who relapsed after allo-HSCT. This female patient had the translocation t(6;11) with transcription of MLL/AF6 fusion mRNA in her leukemic cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Taksin AL, Legrand O, Raffoux E, de Revel T, Thomas X, Contentin N et al. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007; 21: 66–71.

    Article  CAS  Google Scholar 

  2. Mrozek K, Bloomfield CD . Chromosome aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology 2006 Education program book. American Society of Hematology: Washington, DC, 2006, 169–177.

    Google Scholar 

  3. Garrido SM, Bryant E, Appelbaum FR . Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities. Leuk Res 2000; 24: 481–486.

    Article  CAS  Google Scholar 

  4. Larson RA, Sivers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H et al. Final report on the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33 positive acute myeloid leukemia in first recurrence. Cancer 2001; 104: 1442–1452.

    Article  Google Scholar 

  5. Muñoz L, Nomdedéu JF, Villamor N, Guardia R, Colomer D, Ribera JM et al. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells. Leukemia 2003; 17: 76–82.

    Article  Google Scholar 

Download references

Author information

Author notes

  1. H Tamai and Y Shioi: These two authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Nippon Medical School, Tokyo, Japan

    H Tamai, Y Shioi, H Yamaguchi, M Okabe, S Wakita, T Mizuki, K Nakayama, K Inokuchi, K Tajika & K Dan

Authors
  1. H Tamai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y Shioi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Okabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Wakita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T Mizuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Inokuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Tajika
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Dan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Tamai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tamai, H., Shioi, Y., Yamaguchi, H. et al. Treatment of relapsed acute myeloid leukemia with MLL/AF6 fusion after allogeneic hematopoietic stem cell transplantation with gemtuzumab ozogamicin with a long interval followed by donor lymphocyte infusion. Leukemia 22, 1273–1274 (2008). https://doi.org/10.1038/sj.leu.2405029

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405029

This article is cited by

Search

Advanced search

Quick links